Ketoconazole potentiates terfenadine‐induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity
- 1 January 2002
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 87 (2) , 147-159
Abstract
Terfenadine (TF) is a highly potent histamine H1 receptor antagonist that in clinically effective doses is free of significant central nervous system side effects. Ketoconazole (KT) is a worldwide used oral antifungal agent with a broad spectrum of activity against both superficial and systemic mycosis. Simultaneously administration of KT and TF has been reported to induce several potent symptoms including cardiotoxicity, excitotoxicity, inhibition of blood mononuclear cells proliferation, and cardiovascular toxicity. However, the intracellular molecular mechanisms of TF–KT interactions in cells were still uncertain. In this study, we first demonstrated that TF (5–30 μM) induced apoptosis in several types of human cancer cell lines including human hepatoma (Hep G2), colorectal cancer (COLO 205), and fibroblast (CCD 922SK) cells for 24 h. The cellular responses to TF‐induced apoptosis were demonstrated to be associated with the p53‐signaling pathway, including induction of p53, p21/Cip1, p27/Kip1, bax protein expression and inhibition of bcl‐2 protein expression. To realized the role of H1 receptor involved in TF‐induced apoptosis, different H1 receptor antagonists including promethazine, mequitazine, and chlorpheniramin (50–100 μM) were administered and demonstrated that these chemicals cannot induced apoptosis through the H1 receptor signaling pathway. Interestingly, we found that the apoptotic effect of TF (2.5 μM) was significantly potentiated by KT (1 μM) treatment in Hep G2 cells through inhibition of the cytochrome p450 3A4 (CYP 3A4) activity. Such results were demonstrated by decreased of the TF activity with recombinant CYP 3A4, which prepared from baculovirus‐infected insect cells. Our results provide the molecular basis of TF–KT interaction and this information should allow more rational forecasting of the risk for TF therapy during co‐administration of KT. J. Cell. Biochem. 87: 147–159, 2002.Keywords
This publication has 52 references indexed in Scilit:
- Cytochrome P4503A-Dependent Metabolism of Tocopherols and Inhibition by SesaminBiochemical and Biophysical Research Communications, 2000
- Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazoleJournal of Pharmaceutical Sciences, 1998
- Ketoconazole-Induced Apoptosis through P53-Dependent Pathway in Human Colorectal and Hepatocellular Carcinoma Cell LinesToxicology and Applied Pharmacology, 1998
- Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam andN-Desmethyladinazolam in ManJournal of Pharmacy and Pharmacology, 1998
- Suppression of nitric oxide–induced apoptosis by N-acetyl-l-cysteine through modulation of glutathione, bcl-2, and bax protein levelsMolecular Carcinogenesis, 1997
- Induction ofp53 andp21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cellsMolecular Carcinogenesis, 1996
- In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic InteractionThe Journal of Clinical Pharmacology, 1994
- Non-Sedating AntihistaminesAllergy and Asthma Proceedings, 1988
- Hepatic reactions associated with ketoconazole in the United Kingdom.BMJ, 1987
- KETOCONAZOLE FOR PROSTATE CANCERThe Lancet, 1984